1 |
castration-resistant prostate cancer
(3171 times)
|
Neoplasms (1357 times)
|
AR (886 times) PSA (451 times) PCa (418 times)
|
2006 Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.
|
2 |
castration-resistant PCa
(272 times)
|
Neoplasms (113 times)
|
PCa (179 times) AR (101 times) PC (76 times)
|
2008 Mechanisms mediating androgen receptor reactivation after castration.
|
3 |
colorectal peritoneal carcinomatosis
(24 times)
|
General Surgery (10 times)
|
CRS (8 times) PCI (8 times) PIC (5 times)
|
2008 Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?
|
4 |
castration-recurrent PCa
(4 times)
|
Science (1 time)
|
AR (4 times) PCa (3 times) ADT (1 time)
|
2010 Androgen receptor abnormalities in castration-recurrent prostate cancer.
|
5 |
cancer peritoneal carcinomatosis
(3 times)
|
General Surgery (3 times)
|
CRS (3 times) HIPEC (1 time) IPC (1 time)
|
2009 Significance of lymph node metastasis in patients with colorectal cancer peritoneal carcinomatosis.
|
6 |
castration-recurrent/resistant PCa
(3 times)
|
Neoplasms (2 times)
|
DHT (3 times) ADT (2 times) AR (2 times)
|
2011 Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.
|
7 |
Cancer Rehabilitation Physician Consortium
(2 times)
|
Physical and Rehabilitation Medicine (2 times)
|
ACSM (1 time) CRM (1 time)
|
2019 Training and Practice Patterns in Cancer Rehabilitation: A Survey of Physiatrists Specializing in Oncology Care.
|
8 |
cancer, patients often progress to castration-resistant disease
(2 times)
|
Neoplasms (1 time)
|
ADT (1 time) AIS (1 time) AR (1 time)
|
2016 Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
|
9 |
castrate-resistant prostate cancer patients
(2 times)
|
Medicine (1 time)
|
CTCs (1 time) DJD (1 time) GEDI (1 time)
|
2012 Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.
|
10 |
combined rehabilitation and palliative care
(2 times)
|
Medicine (1 time)
|
---
|
2018 [Coordinating rehabilitation and palliative care].
|
11 |
cancer transition from androgen-dependent to androgen-independent state
(1 time)
|
Biochemistry (1 time)
|
ADT (1 time) AR (1 time) EMT (1 time)
|
2015 Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer invivo.
|
12 |
castration-recurrent/resistant prostate cancer
(1 time)
|
Urology (1 time)
|
AND (1 time)
|
2018 Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects.
|
13 |
castration-resistant PCa cell line VCaP
(1 time)
|
Nuclear Medicine (1 time)
|
AA (1 time) ADT (1 time) PCa (1 time)
|
2015 Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy.
|
14 |
centered rectangular photonic-crystal
(1 time)
|
Nanotechnology (1 time)
|
DFB (1 time) HR (1 time) QCLs (1 time)
|
2015 10-W pulsed operation of substrate emitting photonic-crystal quantum cascade laser with very small divergence.
|
15 |
central renal pyelocalyceal complex
(1 time)
|
Urology (1 time)
|
---
|
1979 Nonobstructive fragmentation of central renal pyelocalyceal echo complex.
|
16 |
chemotherapy alone, the treatment of peritoneal carcinomatosis from colorectal cancer
(1 time)
|
General Surgery (1 time)
|
CRS (1 time) IPC (1 time)
|
2013 Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?
|
17 |
chronic radiation proctocolitis
(1 time)
|
Gastroenterology (1 time)
|
APC (1 time)
|
2010 The incidence of bacteraemia after argon plasma coagulation in patients with chronic radiation proctocolitis.
|
18 |
cisplatin/etoposide-resistant prostate cancer
(1 time)
|
Antineoplastic Agents (1 time)
|
G-CSF (1 time) MTD (1 time) TNBC (1 time)
|
2018 A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
|
19 |
concentrates prepared from Channa striatus
(1 time)
|
Chemistry (1 time)
|
---
|
2012 Physico-chemical, amino acid composition, functional and antioxidant properties of roe protein concentrates obtained from Channa striatus and Lates calcarifer.
|
20 |
confound treatment of this 'castration resistant' stage of PCa
(1 time)
|
Neoplasms (1 time)
|
AR (1 time) DBD (1 time) LBD (1 time)
|
2018 Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
|
21 |
consecutive rising PSAs
(1 time)
|
Urology (1 time)
|
ADT (1 time) EHR (1 time) PSADT (1 time)
|
2015 Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
|
22 |
corticosteroid-refractory refractory prostate cancer
(1 time)
|
Nephrology (1 time)
|
ALP (1 time) DEX (1 time) LDH (1 time)
|
2011 Docetaxel as a vital option for corticosteroid-refractory prostate cancer.
|
23 |
CR prostate cancer
(1 time)
|
Biological Science Disciplines (1 time)
|
CR (1 time)
|
2018 Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer.
|
24 |
CRPC N-glycan score
(1 time)
|
Natural Science Disciplines (1 time)
|
AGP (1 time) BPH (1 time) PC (1 time)
|
2019 Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.
|
25 |
cumulated rate of permanent colostomy
(1 time)
|
Neoplasms (1 time)
|
CR (1 time) EBRT (1 time)
|
2012 Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96-02 randomized trial.
|
26 |
hormone-refractory 'castrate-resistant' PC
(1 time)
|
Molecular Biology (1 time)
|
AR (1 time) PCs (1 time) PHB (1 time)
|
2011 Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens.
|